[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu",
    "summary": "In June 2025, Bristol-Myers Squibb (NYSE:BMY) announced positive results from the Phase 3 POETYK PsA-1 trial of Sotyktu, showcasing its efficacy in treating psoriatic arthritis. This significant development likely reinforced investor confidence, reflected in the company's 8% share price increase over the past month. Additionally, the European Commission’s approval of the subcutaneous use of Opdivo and the collaboration with BioNTech for cancer treatment may have further supported the positive...",
    "url": "https://finnhub.io/api/news?id=501ebc3f120d76e6bd5f2ab29398305564d0231bd5ca64521571b95f8fe7e357",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749662526,
      "headline": "Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu",
      "id": 135196639,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "In June 2025, Bristol-Myers Squibb (NYSE:BMY) announced positive results from the Phase 3 POETYK PsA-1 trial of Sotyktu, showcasing its efficacy in treating psoriatic arthritis. This significant development likely reinforced investor confidence, reflected in the company's 8% share price increase over the past month. Additionally, the European Commission’s approval of the subcutaneous use of Opdivo and the collaboration with BioNTech for cancer treatment may have further supported the positive...",
      "url": "https://finnhub.io/api/news?id=501ebc3f120d76e6bd5f2ab29398305564d0231bd5ca64521571b95f8fe7e357"
    }
  },
  {
    "ts": null,
    "headline": "Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel",
    "summary": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: VACCINE ADVISORY COMMITTEE: In an opinion article published by The Wall Street Journal, Robert F. Kennedy Jr. stated, “Vaccines have become a divisive issue in American politics, but there is one thing all parties can agree on: The U.S. faces a crisis of public trust. Whether toward health agenci",
    "url": "https://finnhub.io/api/news?id=0fb2c9884a3d968b1b0c30f15e468bdc5f7226238ff1a399f8ca9a402bd38ad7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749651653,
      "headline": "Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel",
      "id": 135184593,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: VACCINE ADVISORY COMMITTEE: In an opinion article published by The Wall Street Journal, Robert F. Kennedy Jr. stated, “Vaccines have become a divisive issue in American politics, but there is one thing all parties can agree on: The U.S. faces a crisis of public trust. Whether toward health agenci",
      "url": "https://finnhub.io/api/news?id=0fb2c9884a3d968b1b0c30f15e468bdc5f7226238ff1a399f8ca9a402bd38ad7"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ETCompany ParticipantsAdam Lenkowsky -...",
    "url": "https://finnhub.io/api/news?id=2fa5aa046cedbb39d71fc74b08e2d3a6395eb28ceb1daa017bcb96b1448578e4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749649402,
      "headline": "Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)",
      "id": 135192368,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ETCompany ParticipantsAdam Lenkowsky -...",
      "url": "https://finnhub.io/api/news?id=2fa5aa046cedbb39d71fc74b08e2d3a6395eb28ceb1daa017bcb96b1448578e4"
    }
  },
  {
    "ts": null,
    "headline": "Why This 1 Value Stock Could Be a Great Addition to Your Portfolio",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=6dbf2c20beacf6b24106bca2036edcd2d5c865384fb1d7a852e04b2e67b05cbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749649208,
      "headline": "Why This 1 Value Stock Could Be a Great Addition to Your Portfolio",
      "id": 135186519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=6dbf2c20beacf6b24106bca2036edcd2d5c865384fb1d7a852e04b2e67b05cbf"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=6bf5211de32612836a7adb5e9bb8195ac8b1ad83425992ed77ced1cd96246519",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749646802,
      "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 135186521,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=6bf5211de32612836a7adb5e9bb8195ac8b1ad83425992ed77ced1cd96246519"
    }
  },
  {
    "ts": null,
    "headline": "Geron: A Tough First Year For Rytelo, But Not Yet Time To Sell (Downgrade)",
    "summary": "Geron Corporation's Rytelo faces issues in sales and competition. Click for why solid funding, label expansion potential, and upcoming GERN catalysts offer hope.",
    "url": "https://finnhub.io/api/news?id=7d1a1b902ac3943e7a3c6435c3822378f38351e43c1fd2d90ae12a3db173d9ac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749641877,
      "headline": "Geron: A Tough First Year For Rytelo, But Not Yet Time To Sell (Downgrade)",
      "id": 135188680,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1238209683/image_1238209683.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Geron Corporation's Rytelo faces issues in sales and competition. Click for why solid funding, label expansion potential, and upcoming GERN catalysts offer hope.",
      "url": "https://finnhub.io/api/news?id=7d1a1b902ac3943e7a3c6435c3822378f38351e43c1fd2d90ae12a3db173d9ac"
    }
  },
  {
    "ts": null,
    "headline": "Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10",
    "summary": "Presenter SpeechAsad Haider All right. But just right about at time. So let's get started. Welcome to day 3 of our Healthcare Conference. My name is Asad Haider, I'm the U.S. pharmaceutical analyst",
    "url": "https://finnhub.io/api/news?id=a72071d685fd7ac7f2f89aec162e708af425ad1ead63ee70cdeeefb647803ba2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749641716,
      "headline": "Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10",
      "id": 135188314,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Presenter SpeechAsad Haider All right. But just right about at time. So let's get started. Welcome to day 3 of our Healthcare Conference. My name is Asad Haider, I'm the U.S. pharmaceutical analyst",
      "url": "https://finnhub.io/api/news?id=a72071d685fd7ac7f2f89aec162e708af425ad1ead63ee70cdeeefb647803ba2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers bolsters radiopharma portfolio with PhiloChem deal",
    "summary": "The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate cancer that works differently than Novartis’ Pluvicto.",
    "url": "https://finnhub.io/api/news?id=ac9ed1b9129782c3e65dc4d404b67ef04a5595bf52b27838489b8c5cb37bcb03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749640080,
      "headline": "Bristol Myers bolsters radiopharma portfolio with PhiloChem deal",
      "id": 135196641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate cancer that works differently than Novartis’ Pluvicto.",
      "url": "https://finnhub.io/api/news?id=ac9ed1b9129782c3e65dc4d404b67ef04a5595bf52b27838489b8c5cb37bcb03"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis",
    "summary": "PRINCETON, N.J., June 11, 2025--BMS Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu...",
    "url": "https://finnhub.io/api/news?id=2a2df9a9808bd4f3937f839b6796752f5c980bd5caab614d662afa57b2c4abd3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749639540,
      "headline": "Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis",
      "id": 135179487,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., June 11, 2025--BMS Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu...",
      "url": "https://finnhub.io/api/news?id=2a2df9a9808bd4f3937f839b6796752f5c980bd5caab614d662afa57b2c4abd3"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA -1 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis",
    "summary": "Bristol Myers Squibb announced positive data from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis who were not...",
    "url": "https://finnhub.io/api/news?id=b05d4d060dfe19c0ded5d0392d6f1e77a6dbfeceb520c2c4dc107d94453adff4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749631025,
      "headline": "Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA -1 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis",
      "id": 135179171,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb announced positive data from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis who were not...",
      "url": "https://finnhub.io/api/news?id=b05d4d060dfe19c0ded5d0392d6f1e77a6dbfeceb520c2c4dc107d94453adff4"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers' Sotyktu Shows Superiority Over Placebo in Phase 3 Psoriatic Arthritis Trial",
    "summary": "Bristol-Myers Squibb Co: * BRISTOL MYERS SQUIBB PRESENTS LATE-BREAKING DATA FROMPIVOTALPHASE 3 POETYK PSA-1 TRIAL DEMONSTRATING SUPERIORITY OF SOTYKTU COMPARED WITH PLACEBO IN ADULTS...",
    "url": "https://finnhub.io/api/news?id=2c78b6d50f1149092d1e0a5d58c68072bae10139bbe20096caa16a17607ff50a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749625390,
      "headline": "Bristol Myers' Sotyktu Shows Superiority Over Placebo in Phase 3 Psoriatic Arthritis Trial",
      "id": 135178402,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol-Myers Squibb Co: * BRISTOL MYERS SQUIBB PRESENTS LATE-BREAKING DATA FROMPIVOTALPHASE 3 POETYK PSA-1 TRIAL DEMONSTRATING SUPERIORITY OF SOTYKTU COMPARED WITH PLACEBO IN ADULTS...",
      "url": "https://finnhub.io/api/news?id=2c78b6d50f1149092d1e0a5d58c68072bae10139bbe20096caa16a17607ff50a"
    }
  }
]